At the four-day KIMES 2025 exhibition, more than 35,000 products and prototypes were on display. In the clamor, BioWorld engaged with three promising neurological disease-focused companies – Readycure Inc., Neurive Co. Ltd. and Vuno Inc. – that showcased innovative technology for conditions like Alzheimer’s disease and tinnitus at the Seoul-based event.

“One of the many reasons we don’t have effective therapies for AD at the moment ... is that we don’t understand the beginnings of the disease,” Constanze Depp told BioWorld. Understanding those beginnings is likely to be a necessary prerequisite for truly turning the tide on Alzheimer’s disease (AD). “The brain is so bad at repairing itself, and once a neuron is lost, it will most likely not regenerate,” she elaborated. Now, Depp and her colleagues have reported on a contributor to those beginnings.

A team of scientists led by Liang Ge from Tsinghua University have identified a chaperonin subunit CCT2 as a new type of aggrephagy receptor which specifically accelerates the autophagic clearance of solid aggregates independent of ubiquitination, providing a promising therapeutic target for neurodegenerative diseases.